Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial (Q39234563)

10 September 2017

Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial (English)

1 reference

10 September 2017

0 references

1 reference

Priscilla A Hollander

1

1 reference

10 September 2017

Aslam Amod

2

1 reference

10 September 2017

León E Litwak

3

1 reference

10 September 2017

Umesh Chaudhari

4

1 reference

10 September 2017

ARPEGGIO Study Group

5

1 reference

10 September 2017

language of work or name

English

0 references

publication date

15 December 2009

1 reference

10 September 2017

1 reference

10 September 2017

33

1 reference

10 September 2017

3

1 reference

10 September 2017

605-607

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

10 September 2017

start time

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Standards of medical care in diabetes--2007.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2827517

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20009090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20009090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC09-0455

1 reference

release_v6tp6oxjynf2ti3qaxnunwbqwu

10 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v6tp6oxjynf2ti3qaxnunwbqwu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

10 September 2017

1 reference